Abstract

Aminopropanediol (APD), chemically designated as 3-amino-1,2-propanediol (CAS 616-30-8), is a clear, viscous liquid with the molecular formula C₃H₉NO₂ and a molecular weight of 91.11. It serves as a critical intermediate in the synthesis of non-ionic iodinated contrast media—including iohexol and ioversol—used in medical imaging, and as a building block in agrochemical production. According to the Global Aminopropanediol (APD) Market Report 2024–2030, the global market is projected to grow from USD 69 million in 2023 to USD 105 million by 2030, registering a compound annual growth rate of 5.6% over the forecast period. The competitive landscape is exceptionally concentrated: the top three manufacturers—Borregaard, Kashima Chemical, and additional key suppliers—collectively accounted for approximately 74.8% of global revenue in 2023. This analysis examines the compound’s synthesis pathway, its structural dependence on contrast media demand, and the supply concentration that defines competitive dynamics in a niche pharmaceutical intermediate market.

Chemical Architecture and Synthesis Pathway

APD is produced through the reaction of 3-chloro-1,2-propanediol (CPD) with ammonia in a sodium hydroxide alkaline environment, followed by purification steps that remove unreacted intermediates and byproducts. The molecule’s structure—a three-carbon chain bearing both primary amine and vicinal diol functionalities—confers reactivity at multiple sites, enabling its incorporation into complex pharmaceutical scaffolds. In contrast media synthesis, APD serves as the hydrophilic side chain that confers water solubility and reduces osmolality, properties essential for patient tolerance in intravascular administration.

The purity specification is a critical quality attribute. Pharmaceutical-grade APD requires ≥99.5% purity, with ≥99.9% grades available for the most demanding applications . Residual CPD, ammonia, and related impurities must be controlled to levels that do not compromise downstream contrast media synthesis or introduce toxicological risk. This purity requirement, combined with the compound’s hygroscopic nature and viscosity, imposes handling and packaging constraints that favor suppliers with specialized pharmaceutical intermediate capabilities.

Market Scale and Competitive Concentration

The global APD market is forecast to reach USD 105 million by 2030 from a 2023 baseline of USD 69 million, expanding at a CAGR of 5.6%. More recent QYResearch data place the 2024 market at approximately USD 72.4 million, with a 2031 trajectory toward USD 104 million at 5.4% CAGR . Alternative estimates from LP Information place the 2025 market at USD 76.8 million, growing to USD 108 million by 2031 at 5.8% CAGR . Hengzhou Chengsi estimates the 2024 market at approximately RMB 550 million, with a 2031 forecast near RMB 770 million at 5.2% CAGR . The convergence of these forecasts around the mid-single-digit growth range confirms the stable, demand-driven nature of the market.

Competitive concentration is pronounced. In 2023, the top three players held approximately 74.8% of global revenue. Borregaard anchors the competitive field through its Borregaard Synthesis fine chemicals operation, which holds a stated position as market leader for fine chemicals to the contrast media industry . The company’s integrated capabilities span process research, development, and scale-up from laboratory through pilot plant to full-scale production, with R&D facilities in Norway, the USA, and Italy. Kashima Chemical represents the Japanese supply base, leveraging domestic pharmaceutical intermediate expertise. Inner Mongolia Saintchem Chemicals has emerged as a significant Chinese supplier, producing approximately 50 tons of first-class APD monthly with chromatographic purity of 99.7% . The broader supplier landscape includes Yixing Yangyang Plastic Auxiliary, Jiangsu Hetai New Material Technology, and Yangzhou Princechem .

Application Segmentation: Contrast Media as the Anchor Demand

Non-ionic contrast media synthesis constitutes the dominant application for APD, reflecting the compound’s role as a hydrophilic building block in iohexol and ioversol manufacturing. The global iodine contrast media market was valued at USD 4,232 million in 2025, with iohexol representing the largest product segment at over 31% share . This downstream market’s trajectory directly determines APD demand: each contrast media production run consumes APD in stoichiometric proportion, and the growth of diagnostic imaging utilization—particularly in Asia-Pacific, which holds over 41% of the contrast media market—translates into corresponding APD volume growth .

Agrochemical applications constitute the secondary demand segment. APD serves as an intermediate in pesticide synthesis, where its amine and diol functionalities enable incorporation into herbicidal and fungicidal active ingredients. The agrochemical segment is smaller in absolute volume than contrast media but provides demand diversification that partially offsets pharmaceutical market cyclicality.

Market Drivers and Constraints

The primary demand catalyst is the expansion of diagnostic imaging utilization globally. Aging populations, rising prevalence of chronic diseases requiring imaging surveillance, and the growing availability of CT and interventional X-ray procedures in emerging markets are driving contrast media consumption. The Asia-Pacific region’s dominance in contrast media demand—over 41% of the global market—positions Chinese and regional APD suppliers for volume growth even as Western markets mature .

Supply concentration and qualification barriers constitute a structural constraint on market entry. Pharmaceutical customers require extensive qualification of APD suppliers, including documentation of purity profiles, impurity identification, and manufacturing process validation. The cost and time required to qualify a new supplier—often spanning months to years—favor incumbents with established customer relationships and regulatory files. This dynamic reinforces the concentration among Borregaard, Kashima Chemical, and Inner Mongolia Saintchem, and limits the opportunity for new entrants despite the market’s steady growth.

A secondary constraint is the APD market’s dependence on a narrow application base. With contrast media representing the dominant demand segment, the market is exposed to pharmaceutical industry dynamics—pricing pressure on contrast agents, shifts in imaging modality preferences, and generic competition—that are outside the control of intermediate suppliers. The agrochemical segment provides partial diversification but is insufficient to fully offset a downturn in contrast media demand.

Recent Performance and Supply-Side Dynamics

Borregaard’s recent financial disclosures provide insight into the fine chemical intermediates segment that encompasses APD. In the third quarter of 2025, the company reported that fine chemical intermediates delivered a strong result, supported by a more favorable product mix and price increases relative to the prior-year quarter, even as overall Fine Chemicals segment revenue declined due to lower bioethanol prices . This performance suggests that the pharmaceutical intermediate portion of the portfolio, which includes APD, is sustaining pricing and margin discipline despite broader commodity pressures. Borregaard’s positioning as “the market leader for fine chemicals to the contrast media industry” underscores the strategic importance of this segment to its fine chemicals business .

Inner Mongolia Saintchem’s disclosed pricing of RMB 62,000 per unit (unit specification not specified) and its monthly production of 50 tons at 99.7% purity provide a benchmark for Chinese supply economics . The company’s emphasis on “first-class” purity and consistent monthly output positions it as a credible alternative to European and Japanese suppliers for cost-sensitive customers, though qualification for regulated pharmaceutical markets remains a gating factor.

Outlook Through 2030

The APD market trajectory through 2030 is characterized by steady, moderate growth anchored in contrast media demand. The 5.6% CAGR reflects the compound’s status as a mature pharmaceutical intermediate with a stable application base rather than a high-growth specialty chemical. The competitive landscape will be shaped by three forces: Borregaard’s incumbency in contrast media supply chains and its process development capabilities; the ascent of Chinese suppliers in cost-sensitive and domestic markets; and the pace of contrast media adoption in Asia-Pacific, which determines the geographic distribution of demand growth. The market’s fundamental value proposition—a high-purity, reliably supplied building block for life-saving diagnostic agents—is unlikely to be displaced by alternative chemistries within the forecast horizon. The competitive question is whether Chinese suppliers can achieve the regulatory documentation and quality systems required for qualification with multinational contrast media manufacturers, or whether the market remains segmented between Western-qualified supply and domestic Chinese consumption.

Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp